Scientists have developed a technique that could lead to therapies for pain relief in people with intractable pain, potentially including cancer-related pain.

A team of scientists at Kyoto University’s Institute for Integrated Cell-Material Sciences (iCeMS) has developed a novel technique using tiny gold rods to target pain receptors.

Gold nanorods are tiny rods that are 1-100 nanometers wide and long. In comparison, a human hair is 100,000 nanometers wide. The team coated gold nanorods with a special type of protein that transports fat within the body known as a lipoprotein. This allowed the nanorods to bind efficiently to nerve cell membranes bearing a pain receptor called TRPV1 (transient receptor potential vanilloid type 1). Near-infrared light was then applied to the nanorod-coated pain receptors. The nanorods heated up, activating the pain receptors to allow an influx of calcium ions through the membrane. Prolonged activation of TRPV1 is known to subsequently lead to their desensitization, bringing pain relief. Importantly, heating the gold nanorods enabled safe activation of the TRPV1 pain receptors alone, without affecting the membrane in which they lie.

Previous studies had shown that magnetic nanoparticles (tiny particles in the nano-range made out of magnetic materials) are also able to activate TRPV1 receptors by applying a magnetic field. The target cells in this method, however, require genetic modification for it to work. Using lipoprotein-coated gold nanorods does not require genetic modification of the target cells. Also, the nanorods were found to have at least 1,000 times greater efficiency than magnetic nanoparticles in heat generation and in activating TRPV1 receptors.

‘The gold nanorods can be retained in the body for a prolonged period,’ says Tatsuya Murakami, the principal investigator of this study. ‘Local injection of our gold nanorods might enable repetitive and on-demand treatment for people experiencing intractable pain because prior genetic engineering of the target cells is unnecessary.’ Kyoto University iCeMS

A new nanoparticle developed by University of Michigan researchers could be the key to a targeted therapy for cardiac arrhythmia, a condition that causes the heart to beat erratically and can lead to heart attack and stroke.

Advances over the past 20 years have made cardiac ablation successful and safe for stopping abnormal heartbeats, called arrhythmias, but it remains highly complex.

In studies conducted on rodents and sheep, the UM team found that the treatment successfully kills the cells that cause cardiac arrhythmia while leaving surrounding cells unharmed.

Cardiac arrhythmia is caused by malfunctions in a certain type of heart muscle cell, which normally helps regulate the heartbeat. Today, the disease is usually treated with drugs, which can have serious side effects. It can also be treated with a procedure called cardiac ablation that burns away the malfunctioning cells using a highpowered laser that

Dr Gerald Antoch, professor of radiology and chairman of the department of diagnostic and interventional radiology at D

Engineers at the University of California, San Diego, have developed a mouth guard that can monitor health markers, such as lactate, cortisol and uric acid, in saliva and transmit the information wirelessly to a smart phone, laptop or tablet.
The technology, which is at a proof-of-concept stage, could be used to monitor patients continuously without invasive procedures, as well as to monitor athletes

Researchers at Thomas Jefferson University showed that a simple questionnaire, evaluation and pulse-oximetry monitoring can lead to early detection of sleep apnea in patients hospitalized for congestive heart failure (CHF).